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ABSTRACT
....................................................................................................................................................
Objective To illustrate an in silico integration of epidemiologic and genetic evidence that is being developed at the Center for Devices and
Radiological Health/US Food and Drug Administration as part of regulatory research on postmarket device performance. In addition to using con-
ventional epidemiologic evidence from registries, this innovative approach explores the vast potential of open-access omics databases for identify-
ing genetic evidence pertaining to devices.
Material and methods A retrospective analysis of Agency for Healthcare Research and Quality (AHRQ)/Healthcare Cost and Utilization Project
(HCUPNet) data (2002–2011) was focused on the ventilation-related iatrogenic pneumothorax (Vent-IP) outcome in discharges with mechanical
ventilation (MV) and continuous positive airway pressure (CPAP). The derived epidemiologic evidence was analyzed in conjunction with pre-existing
genomic data from Gene Expression Omnibus/National Center for Biotechnology Information and other databases.
Results AHRQ/HCUPNet epidemiologic evidence showed that annual occurrence of Vent-IP did not decrease over a decade. While the Vent-IP risk
associated with noninvasive CPAP comprised about 0.5%, the Vent-IP risk due to longer-term MV reached 2%. Along with MV posing an indepen-
dent risk for Vent-IP, female sex and white race were found to be effect modifiers, resulting in the highest Vent-IP risk among mechanically venti-
lated white females. The Vent-IP risk was also potentiated by comorbidities associated with spontaneous pneumothorax (SP) and fibrosis.
Consistent with the epidemiologic evidence, expression profiling in a number of animal models showed that the expression of several collagens
and other SP/fibrosis-related genes was modified by ventilation settings.
Conclusion Integration of complementary genetic evidence into epidemiologic analysis can lead to a cost- and time-efficient discovery of the risk
predictors and markers and thus can facilitate more efficient marker-based evaluation of medical product performance.
....................................................................................................................................................
Keywords: In silico evidence integration using big data approaches, Translational Epidemiology, Repurposing and re-utilization of pre-existing
genetic data, Medical device safety biomarkers
INTRODUCTION
As part of a public health commitment to advancing the safety and ef-
fectiveness of medical products, the US Food and Drug Administration
(FDA) makes continuous efforts in developing new approaches to reg-
ulatory science. The Center for Devices and Radiological Health
(CDRH) has recently initiated a program on the medical device devel-
opment tools (eg, in vitro tests, markers, etc.) that are expected to
strengthen regulatory decision-making by generating more predictive
evidence on medical device performance. The CDRH’s regulatory
science initiatives include Medical Device Epidemiology Network part-
nerships, which serve the center’s vision for US postmarket surveil-
lance that can accurately characterize real-world performance and
thereby deliver “the right device to the right person.” New methodolo-
gies harnessing recent advances in bioinformatics and genomics can
be particularly effective in identifying clinical outcomes and molecular
markers that can serve as reliable and measurable study endpoints in-
dicative of real-world performance. These new evidentiary approaches
can facilitate more individualized risk-benefit assessment, thus align-
ing with the recently announced Precision Medicine initiative.
This article illustrates an in silico approach to evidence gathering
and analysis that is being developed at the Division of Epidemiology of
CDRH as part of the regulatory research efforts aimed at strengthening
postmarket surveillance on medical devices. In addition to employing
epidemiologic evidence from conventional sources such as registries,
this innovative approach explores pre-existing open-source omics data
for identifying molecular markers that have a potential for improving
device safety in real-world settings. The current illustration is focused
on iatrogenic pneumothorax (IP) as a device-related adverse event
with considerable health impact.
Pneumothorax is a potentially fatal complication in patients who re-
quire mechanical ventilation (MV) support: the incidence of pneumothorax
in patients with acute respiratory distress disorder (ARDS) in the ICU set-
ting can be as high as 50%, with a mortality rate of 66%.1 Since pneumo-
thorax can have an iatrogenic origin, it is particularly important as a
patient safety indicator developed by the Agency for Healthcare Research
and Quality (AHRQ). IP observed rate (per 100 000) was shown to be
slightly higher in females than males (9.03 and 7.30, respectively) and
about 24 times higher in patients 75 and older compared to 18-to-39-
year-olds (1.61 and 38.05, respectively).2 Although an AHRQ-based study
showed a decreasing trend from 1998 to 2007 for the risk-adjusted IP
rate,3 the risk-adjusted IP rate based on Veterans Health Administration
(VHA) data showed an increase from 2001 to 2004.4 A review of pneumo-
thorax cases at one VHA medical center (1983–1988) showed that the in-
cidence of IP may exceed that of spontaneous pneumothorax (SP).5
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About 21% of IP cases from the Nationwide Inpatient Sample (NIS)
were attributed to respiratory intubation and MV,6 pointing at the impact
of ventilation-related IP (Vent-IP) on health outcomes around the United
States. Vent-IP impact on patient safety was also shown outside of the
United States. In a French study from the 1990s,7 IP accounted for
38.2% of 217 ICU cases with pneumothorax, and Vent-IP in particular
was mostly caused by special ventilatory techniques involving positive
end-expiratory pressure (PEEP) and was associated with less favorable
outcomes and higher mortality. In a more recent Turkish study,8 analysis
of 12 010 invasive procedures identified IP in 164 cases, 9.1% of which
were considered as Vent-IP caused by barotrauma. A recent large study
from Taiwan9 showed a relatively low Vent-IP incidence (0.4%, or 124/
31 660); however, in-hospital mortality was higher in Vent-IP patients
compared to mechanically ventilated patients without pneumothorax
(77.4% versus 13.7%, P< .001) or to patients with nonventilation pneu-
mothorax (77.4% versus 29.4%, P< .001). In a recent Brazilian study,10
half of the IP cases (9/20 among 645 patients) identified in the pediatric
ICU were characterized as Vent-IP.
Although Vent-IP is a relatively rare event in intubated patients with
normal lungs, and most of the patients with Vent-IP have underlying
lung disease,11 its prompt recognition and treatment is important for the
safety of ventilatory support. Vent-IP is mostly caused by high-pressure
air as a result of imbalanced ventilation. Optimal settings for PEEP and
tidal volume are paramount for avoiding volutrauma and atelectotrauma.
While MV was the leading cause of IP in the 1970s, subsequent imple-
mentation of new lung-protective ventilation strategies utilizing low tidal
volumes and PEEP essentially reduced the Vent-IP occurrence.12
However, a recent Kaiser Permanente CREST Network study,13 which
analyzed 1249 patient encounters in US community emergency depart-
ments, showed a 16-fold increase (0.1–1.6%, P< .01) in IP incidence
when positive pressure ventilation was applied. According to a US
study on the effectiveness of ventilation modes in real-world settings,14
use of noninvasive ventilation versus invasive MV can greatly
lower Vent-IP risk (0.05% versus 0.5%, P< .001); however, the varying
rates of noninvasive ventilation among US hospitals impede potential
benefits.
Thus, Vent-IP is a device-related adverse event that can still have
considerable health impact, despite the implementation of lung-pro-
tective ventilation strategies. As a result, we sought to conduct a pilot
on the development of a new in silico framework for gathering and an-
alyzing evidence which would (1) allow more comprehensive evalua-
tion of Vent-IP, and (2) outline possibilities for new preventive
measures that could refine the risk-benefit assessment of ventilatory
strategies. Our search strategy for Vent-IP–related evidence was
based on a hypothesis that the factors that are known to contribute to
SP may also contribute to Vent-IP. Subsequently, SP/fibrosis-related
diseases15 and corresponding genes (as shown in Supplement 1)
were used for deriving and integrating both epidemiologic and genetic
evidence pertaining to Vent-IP. As shown in Figure 1, which outlines
the evidence streams in this study, the epidemiological evidence
showed that continuing occurrence of Vent-IP among ventilation-in-
volving NIS/AHRQ discharges was substantial and occurrence of Vent-
IP was related to factors with potential genetic background, such as
sex/ethnicity and SP/fibrosis comorbidities. Consistent with the study
hypothesis, the cross-species genetic evidence from a number of
in vivo models demonstrated that SP/fibrosis-related genes are
modified by ventilation-related settings and therefore can reflect venti-
lation-related responses and adverse events. As a result, the com-
bined evidence from both epidemiologic and genetic streams
indicated potential risk modifiers and markers that can be used for the
prevention or mitigation of Vent-IP and other ventilation-related
injuries.
METHODS
Epidemiological study sample, variables, and outcomes
Data collected by the NIS (called the Nationwide Inpatient Sample prior
to 2012, and the National Inpatient Sample thereafter) from the AHRQ
from 2002–2011 were used to analyze all available records on ventila-
tion-related procedures with regard to IP. The IP population was first
classified by using a discharge diagnosis of IP, as defined by the
International Classification of Diseases, 9th Revision (ICD-9) code
512.1. Since this ICD-9 code in isolation is not sufficiently specific for
the detection of ventilation-related complications, it was used in con-
junction with the ICD-9 codes for ventilatory procedures. Thus, the pri-
mary outcome of interest was Vent-IP and the primary exposures of
interest were the following ventilatory procedures, used separately or
in combination: noninvasive MV or continuous positive air pressure
(CPAP) (ICD-9 93.90), continuous invasive MV for less than 96 consec-
utive hours (MV< 96 h) (ICD-9 96.71), and continuous invasive MV for
96 consecutive hours or more (MV> 96 h) (ICD-9 96.72).
The main demographics-related covariates of interest were sex
(male, female) and race/ethnicity (White, Black, Hispanic, Asian,
Native American, or other). As a result of the stated hypothesis, the
main comorbidity-related covariates of interest were postinflammatory
and idiopathic forms of pulmonary fibrosis (ICD-9 515 and 516.31, re-
spectively) as well as genetic diseases associated with SP: cystic fi-
brosis (ICD-9 277.02, 277.09), Ehlers-Danlos syndrome (ICD-9
756.83), Marfan syndrome (ICD-9 759.82), homocystinuria (ICD-9
270.4), alpha-1-antitrypsin deficiency (ICD-9 273.4), and Birt-Hogg-
Dube syndrome (ICD-9 759.89). In order to better characterize the
study sample and control for potential confounders, other available pa-
tient-related variables (eg, age, obesity, and obesity-related comorbid-
ities) were used (see Supplement 2 for more details).
Statistical data analysis
SAS 9.3 (SAS Institute, Cary, NC, USA) was used to determine the risk
distribution of IP by ventilation type, sex, and race/ethnicity.
Unweighted frequency tables were used to obtain the prevalence of IP
among each subgroup; contingency tables were used to obtain corre-
sponding pairwise odds ratios. Multivariable logistic regression was
used to determine the association between IP and ventilation type,
with or without the covariates of interest in the unweighted data.
Gene expression profiling
Gene Expression Omnibus (GEO), an open-access genomics data re-
pository from the National Center for Biotechnology Information (NCBI),
was used as the main source for in silico discovery of potential
Figure 1: In silico framework on epidemiological and genetic
evidence on Vent-IP.
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molecular markers for Vent-IP and other ventilation-associated ad-
verse events. The GEO Datasets and Profiles were queried using
search terms with SP/fibrosis-related gene names (eg, serpinA1, col-
lagen, etc.) and ventilation-related keywords (eg, ventilat*). After con-
ducting queries and identifying a number (x5) of animal studies
mimicking the effects of ventilation, GEO tools such as Cluster
Heatmaps, Find Genes, Profile Charts, Profile Neighbors, and T-test
Sample Comparison were used for the expression analysis of curated
datasets. The GEO2R was additionally used for identifying the lists of
differentially expressed genes for further analysis. Some of the noncu-
rated GEO datasets (with no available precomputed gene profile char-
acteristics) were downloaded and analyzed using open-access
GenePattern software from the Broad Institute at Harvard and MIT. In
addition to GEO/NCBI, the gene expression profiling involved studies
available from NextBio (Illumina). The lists of the genes differentially
expressed across experimental conditions were ordered by signifi-
cance and further analyzed using Ingenuity Pathway Analysis (IPA,
Qiagen), including the knowledge base and tools such as Compare
and Venn diagram, Core/Tox Analyses, Biomarker Filters, and Species/
Tissue Expression Overlays.
RESULTS
Epidemiologic evidence
Our preliminary analysis of the AHRQ data (1994–2012) using online
tools from the Healthcare Cost and Utilization Project (complete results
of the HCUPNet-based analysis can be found in Supplements 3 and 4)
showed that the IP rate of discharges per 100 000 based on all listed
diagnoses varied from 29.2 in 1996 to 18.2 in 2012, mostly fluctuat-
ing around the level of 21 per 100 000 since the year 2000. The IP
rate based on principal diagnosis was expectedly lower, but remained
steady and even slightly increased, reaching levels of 3.7–3.4 per
100 000 in 2009–2012. The in-hospital mortality percentage associ-
ated with IP as a principal diagnosis decreased from 2.65% in 1997 to
1.49% in 2005, and fluctuated around 1–1.7% up to 2012.
Our further SAS-based analysis of AHRQ data (2002–2011) fo-
cused on the Vent-IP population. On average, Vent-IP was found in
0.88% (22 930/2 596 533) of all discharges involving single or com-
bined ventilation procedures. (The AHRQ-based frequencies for each
ventilation type and their combinations as well as the corresponding
Vent-IP frequencies can be found in Supplement 5.) However, Vent-IP
rates varied substantially depending on ventilation type. Annual Vent-
IP occurrence remained expectedly low in noninvasive CPAP, espe-
cially compared to longer-term invasive MV> 96 h (Figure 2). The in-
creased odds ratios (OR, 95% CI) for MV-associated Vent-IP were 5.40
(5.11–5.71) and 2.72 (2.57–2.88) for MV> 96 h and MV< 96 h, re-
spectively. Although discharges with a single CPAP or MV procedure
comprised the majority of Vent-IP cases, the Vent-IP frequency was
higher among discharges with the combined ventilation procedures in-
volving longer-term MV> 96 h (Figure 3).
In addition to the ventilation type, the Vent-IP risk was affected by
patient demographics. Vent-IP occurred more frequently in females
than in males (0.95% versus 0.82%, respectively) and in Whites than
in Hispanics or Blacks (0.99% versus 0.72% and 0.68%, respectively).
The effects of ventilation as a primary exposure and the modifier role
of demographic factors were further explored using multivariable lo-
gistic regression (Figure 4A). Regardless of sex or race/ethnicity, long-
lasting invasive ventilation (MV> 96 h) posed the highest risk of Vent-
IP when compared to shorter-term MV and noninvasive CPAP. With
the amplified effects of sex and race/ethnicity, Vent-IP occurrence
reached 2% among White females on MV> 96 h. White females in
general had the highest Vent-IP risk, compared to all other subgroups
(1.08% versus 0.82%, OR¼ 1.33, 95% CI, 1.29-1.36, v2¼ 386.41,
P< .0001) and especially Hispanic males, who had the lowest Vent-IP
risk (1.08% versus 0.66%, OR¼ 1.66, 95% CI, 1.54-1.78,
v2¼ 189.30, P< .0001).
To explore the possible role of comorbidities as additional effect
modifiers, the risk of Vent-IP was assessed with regard to pulmonary
fibrosis and genetic diseases indicative of SP. (A table showing SP dis-
eases15 can be found in Supplement 1.) Figure 4B summarizes the
main SP/fibrosis comorbidities that essentially increased Vent-IP risk.
Even the average risk of Vent-IP among all discharges with SP/fibrosis
was 2.5 times higher than that in the entire ventilated population
(2.14% and 0.88%, respectively; P< .0001). Among a total of 107
discharges listing 1 of the SP diseases, discharges with both Vent-IP
and Birt-Hogg-Dube syndrome were most frequent. However, the
highest risks for Vent-IP were posed by Marfan syndrome (3.45%,
OR¼ 3.88; v2¼ 45.40, P< .0001) and cystic fibrosis (CF), based on
2 ICD-9 codes (1.85%, OR¼ 2.11, v2¼ 16.07, P< .0001 and 2.17%,
OR¼ 2.44, v2¼ 4.16, P< .0414).
Pro-fibrotic changes were shown to contribute to ventilation-in-
duced or ventilated-associated lung injury,16 (VILI/VALI, used here in-
terchangeably to follow the terms used in original studies). Consistent
with that, both idiopathic and postinflammatory forms of pulmonary fi-
brosis (IPF and PPF), which in some cases may have a genetic back-
ground,17 also enhanced the risk of Vent-IP (OR¼ 4.01, v2¼ 13.08,
P< .0003 and OR¼ 2.57, v2¼ 819.95, P< .0001, respectively).
Although IPF/PPF-Vent-IP, with a total of 912 cases, was more
prevalent than SP-Vent-IP, it did not show the White female predomi-
nance that was found in the total Vent-IP population. On the other
hand, CF-Vent-IP was more frequent among White females, and this
predominance was slightly higher among White CF patients with Vent-
IP versus their counterparts without Vent-IP (F/M ratios 1.7 and 1.3,
respectively; NS). Unlike CF-Vent-IP, Marfan-Vent-IP showed a pre-
dominance of White males.
As a result of additional analyses for controlling potential confoun-
ders (Supplement 2), MV was confirmed to independently increase the
risk of Vent-IP: the odds of having Vent-IP were 3.6 times higher
among patients on MV than on CPAP. After adjusting for all potential
confounders used, the female sex and the presence of pulmonary fi-
brosis or SP-related genetic disease was still associated with in-
creased Vent-IP risk, and non-White ethnicities were associated with
decreased Vent-IP risk. In addition, age was shown to increase Vent-
IP risk. Consistent with the demonstrated Vent-IP effect modification
by demographic factors and SP/fibrosis comorbidities, SP in neonates
was associated with the White race.18 SP patients were also shown to
Figure 2: Annual Vent-IP rates (%) among discharges
(AHRQ, 2002–2011) with noninvasive ventilation (CPAP), in-
vasive mechanical ventilation (MV< 96 h and MV> 96 h), or
combined ventilation procedures (Combined).
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be taller19,20 and slenderer,21 supporting the plausibility of race- and
sex-associated effects in development of both SP and Vent-IP.
Physical characteristics such as weight and height are not available in
the NIS database. However, we hypothesized that obese patients could
have decreased risk of IP. Obesity and some obesity-related comorbid-
ities were added to the covariates of interest and, as expected, their
presence was associated with decreased Vent-IP risk (Supplement 2).
Thus, the AHRQ-based epidemiologic evidence showed that Vent-IP
is an adverse event with continuous impact on the safety of ventilatory
support, and pointed to White females as a subpopulation most suscep-
tible to development of Vent-IP. Taken together, Vent-IP risk modification
by race, sex and body build related factors, as well as by SP/fibrosis-re-
lated diseases with a genetic background, suggests a possible role of
genetically determined factors in the development of Vent-IP.
Genetic evidence
Next, using a GEO/GenePattern/IPA-based analytic algorithm and
NCBI/GEO data from a number of animal models mimicking in vivo
ventilation effects, we showed that the expression profiles of some
SP-associated genes (eg, collagens) were modified by ventilation set-
tings of tidal volume and pressure.
Multiple collagen family members (COL1A1, COL1A2, COL3A1,
COL4A1, COL4A2, COL5A2, and COL15A1) were found among the
genes significantly (P< .001) upregulated by high tidal volume ventila-
tion in VALI-resistant versus VALI-sensitive rats. Consistent with that,
several collagens (COL1A1, COL1A2, COL3A1, COL5A1, and COL5A2)
were significantly (P< .01) downregulated in VILI-rats versus control
rats. Based on these cross-validating results from 2 independent stud-
ies (GEO: GDS2709 and GDS1241), COL1A1, COL1A2, COL3A1, and
COL5A2 were identified as the most plausible VILI-marker candidates
among the collagen family. Remarkably, 3 of these collagens,
COL1A1, COL1A2, and COL3A1, are involved in SP-associated Ehlers-
Danlos and atypical Marfan syndromes. In addition to a similar down-
regulation of these 3 collagens, VILI was characterized by upregulation
of another SP-gene, SerpinA1 (Figure 5A). A low baseline expression
of the 3 SP-associated collagens in VALI-sensitive rats was further re-
duced by high tidal volume ventilation. Consistent with that, a higher
baseline expression of the collagens in VALI-resistant rats was further
increased by high tidal volume ventilation (Figure 5B). In addition to
the collagens, high tidal volume ventilation modified the expression of
SerpinA1 (alpha-antitrypsin deficiency), Fbn1 (Marfan syndrome), and
Flcn (Birt-Hogg-Dube´ syndrome).
Among other ventilation-related alterations (Figure 5C), SerpinA1
(which was induced in VILI- and concordantly reduced in VALI-sensi-
tive rats) was shown to be upregulated in rats ventilated with 100%
oxygen. In ventilated mice, Flcn was slightly increased by MV and de-
creased by MVþ LPS (a treatment simulating ventilation-associated
pneumonia), and the causative gene for CF, CFTR, was induced by MV
and further upregulated by MVþ LPS.
Additional NextBio-based profiling (data shown in Supplement 6) on
Flcn (the causative gene for Birt-Hogg-Dube´ syndrome) showed that hu-
man Flcn was increased in patients with IPF, and murine Flcn was re-
duced in a model of hyperoxia-induced bronchopulmonary dysplasia,
also known as “ventilator lung in newborn” (http://www.ncbi.nlm.nih.
gov/pubmedhealth/PMHT0022889/; accessed on March 15, 2015).
The GEO/NCBI-based expression profiling on IPF patients (data
shown in Supplements 6 and 7) showed an upregulation trend for
FBN1 and multiple collagens (COL6A1, COL6A2, COL6A3, COL12A1,
COL14A1, and COL16A1), including COL15A1 (Figure 5D), which was
upregulated by the high tidal volume in VALI-resistant rats (data not
shown). The collagen alterations in IPF included a slight upregulation
of antiangiogenic COL18A1 (data not shown), whose upregulation was
also shown in postmortem lung samples from ventilated preterm in-
fants and was considered part of the angiogenic shift and deficient
alveolarization in infants with bronchopulmonary dysplasia.22 Further
confirming the ventilation-related collagen alterations, elevated Col1A1
was shown to be part of the pro-fibrogenic profile in murine VILI,23
and elevated ratios of type 1/3 collagens were shown in the postmor-
tem lung samples from ventilated neonates with respiratory distress.24
Fibrotic alterations in general are indicative of collagen synthesis acti-
vation and collagenase inhibition, which are considered key events in
VILI-related lung remodeling.16
To explore the biological relevance of the identified marker candi-
dates and their potential utility in a clinical setting, we also examined
their links to lung pathophysiology and assessed their detectability in
human biofluids. The IPA network of SP/fibrosis-genes was associated
with respiratory pathways and biofunctions such as the NRF2-medi-
ated oxidative stress response (FLCN) and the morphology (including
abnormal) of respiratory system and lung development (FBN1, CFTR,
and COL3A1). According to IPA biofluid expression overlay, most of the
collagens as well as FBN1, SERPINA1, and CFTR can be detected in
blood, plasma/serum, urine, and/or sputum.
Thus, the genetic evidence compiled from a number of indepen-
dent (human and animal) in vivo models showed that numerous
SP/fibrosis-genes (FBN1, FLCN, SERPINA1, and collagens such as
COL1A1, COL1A2, and COL3A1) are responsive to ventilation settings
(tidal volume and pressure) and therefore can be indicative of ventila-
tion-related lung injuries.
DISCUSSION
This pilot encompasses a translational continuum that is aimed at
moving discoveries on Vent-IP risk factors and markers from the start-
ing phase of in silico research to the end phase of new ventilation
safety–related health applications. The following discussion provides
evidence-based assessment of the projected scope of Vent-IP health
impact and the value of Vent-IP marker/predictor-based applications
for health practices. As a necessary intermediate step in the transla-
tional continuum, this article attempts to disseminate current research
results for further development and implementation of evidence-based
guidelines on Vent-IP management. This article also outlines next
steps (eg, implementation of a new Vent-IP–specific ICD code) that
are needed for assessing the real-world impact of Vent-IP and the
Figure 3: Vent-IP frequencies (%) among discharges (AHRQ,
2002–2011) with single or combined ventilation procedures.
The left axis shows percentages for the ventilation proce-
dures and the right axis shows percentages for the corre-
sponding Vent-IP rates.
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expected mitigating effects from clinical implementation of Vent-IP
risk predictors and markers. Of particular use here would be active
surveillance methodology to carefully characterize Vent-IP cases and
matched patients with ventilator use without IP, which would allow
validation of the current study findings and evaluation of real-world
outcomes in patients stratified by putative Vent-IP risk predictors and
markers.
Since the NIS represents only a 20% stratified sample of US com-
munity hospitals (sample size can be verified at http://www.hcup-us.
ahrq.gov/nisoverview.jsp; accessed on March 13, 2015), the overall
Vent-IP frequency found in this study, 22 930 cases in 10 years (more
details in Supplement 5) is representative of approximately one-fifth of
the all ventilation-related discharges. Without formal weighting, the
number of in-hospital Vent-IP cases around the United States can be
roughly estimated at 11 500 per year. Meanwhile, the total incidence of
Vent-IP may be even higher due to possible cases resulting from home
use of ventilatory devices. It should also be taken into account that
baseline Vent-IP rates can be further exacerbated under circumstances
requiring mass ventilatory support, eg, respiratory epidemics. The
sizable scope of this projected Vent-IP health impact warrants imple-
mentation of a new ICD code that would be specific to ventilation-asso-
ciated IP (similar to ventilator-associated pneumonia, ICD-9 997.31 and
ICD-10 J95.851) and that would allow more effective surveillance of
Vent-IP compared to the currently used ICD-9 code (512.1), which in-
corporates all IP cases regardless of the causative procedure.
In addition to the impact of Vent-IP per se, a comprehensive risk
assessment of ventilation-related adverse events should include other
possible lung injuries. Positive pressure can contribute to the develop-
ment of Vent-IP in 2 ways.13 First, positive pressure barotrauma can
directly cause Vent-IP (this occurs mostly in patients with an underly-
ing chronic pulmonary disease). Second, positive pressure ventilation
can enlarge the size of existing pneumothoraces, or even transform
some occult abnormalities into a Vent-IP. In any event, Vent-IP occur-
rence carries a greater risk of serious, even life-threatening baro-
trauma, indicating the risk for additional adverse outcomes such as
ventilator-associated pneumonia or VILI. Thus, Vent-IP risk predictors
and markers could have larger implications for ventilation-related ad-
verse outcomes in general.
Figure 4: Patient demographics and comorbidities as Vent-IP effect modifiers.(A) Vent-IP occurrence (%) among discharges stratified by
ventilation type, sex, and race/ethnicity (AHRQ, 2002–2011). (B) Vent-IP occurrence (OR, with 95% CI as red bars) among discharges
with SP/fibrosis comorbidities (AHRQ, 2002–2011).
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The collagen markers in particular can be applicable to preterm in-
fants, who, when exposed to oxygen and ventilation, are at risk for de-
veloping ventilation-related complications such as bronchopulmonary
dysplasia, with subsequent chronic lung disease due to arrested alve-
olar development and dysmorphic angiogenesis.22 In a study on pa-
tients with ARDS, evidence of collagen biosynthesis with altered
collagen expression was shown to be part of the early-ARDS proteo-
mic profile that differentiated survivors from nonsurvivors.25 Despite
the implementation of lung-protective ventilation strategies, ARDS,
which is usually indistinguishable from VILI/VALI,26 continues to be a
major health care problem, affecting more than 190 000 people in the
United States annually and causing a mortality rate of 27–45%.27
Since severe fibroproliferative lung disease has been associated with
a poor prognosis, with high mortality or prolonged ventilator depen-
dence, Vent-IP/VILI markers enabling the mechanistic understanding
and monitoring of ventilation-caused fibroproliferation can be particu-
larly useful in developing preventive/attenuating tactics aimed at im-
proving ventilation-related health outcomes.
Knowing the exact health care impact of ventilation-related compli-
cations can help with making more informed clinical and regulatory
decisions pertaining to ventilatory support. Implementation of validated
Vent-IP risk predictors can individualize risk-benefit assessment (eg,
Figure 5: Ventilation-related expression profiling of genes associated with spontaneous pneumothorax and pulmonary fibrosis. A) Gene
expression of collagen family members (Col1A1, Col1A2, and Col3A1) and SerpinA1 in lung tissue samples from ventilation-induced/as-
sociated lung injury model (GEO:GDS1241, rat). B) Gene expression of collagen family members (Col1A1, Col1A2, and Col3A1),
SerpinA1, Fbn1, and Flcn in lung tissue samples from ventilation-induced/associated lung injury resistant versus sensitive rat strains
(GEO:GDS2709). (C) Gene expression of SerpinA1, Flcn, and CFTR in lung tissue samples from other ventilation-related animal models
(GEO:GDS64, top; GDS:1276, middle and bottom). D) Gene expression of FBN1 and collagen COL15A1 in lung biopsy samples from pa-
tients with idiopathic pulmonary fibrosis versus controls (GEO:GDS1252).
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identifying high-risk patients who are less tolerant to certain ventila-
tion tactics) and can shape the manner in which ventilatory procedures
are explained to patients (eg, as part of the informed consent process).
Many cases of Vent-IP are preventable, and confirmation of the dis-
criminatory power of Vent-IP risk predictors/markers in real-world set-
tings can be a first step in minimizing Vent-IP incidence. As can be
found in the Genetic Testing registry (http://www.ncbi.nlm.nih.gov/gtr/
tests/?term¼collagen; accessed on March 13, 2015), a number of the
currently used diagnostic/prognostic tests incorporate collagens and
other potential Vent-IP markers and therefore can be leveraged for de-
velopment of clinically applicable Vent-IP/VILI tests. Implementation of
putative Vent-IP/VILI markers that are detectable by routine noninva-
sive techniques can represent a next benchmark for enhancing the
safety of ventilatory support since the implementation of lung-protec-
tive ventilatory strategies.
Although our analysis showed a higher association of Vent-IP with
pulmonary fibrosis than with SPs, the carrier frequency for CF alone
(which, unlike many SP-diseases, is an autosomal-recessive disease)
can confer a significant population risk for Vent-IP. About 1 in every
20 Americans is an asymptomatic carrier of the abnormal CFTR gene
(http://www.cdc.gov/excite/ScienceAmbassador/ambassador_pgm/
lessonplans/high_school/Am%20I%20a%20Carrier%20for%20Cystic
%20Fibrosis/Cystic_Fibrosis_Fact_Sheet.pdf). Concordant to the sex/
ethnicity trends identified for Vent-IP, CF is more prevalent among
Caucasians, and it results in more severe lung disease in females. As
a confirmation of possible functional and clinical effects due to CFTR
heterozygosity, delta-F508 carriers were shown to have increased
risks for diabetes28 and asthma.29 Moreover, PEEP-volume curves
measured in Cftrþ/- mice showed the presence of a gene dosage
effect that results in greater lung compliance (lower elastance) in Cftr-
heterozygotes compared to knockout and wild-type.30 These data
strongly suggest that CF carriers may represent an essential subpopu-
lation that, when placed on ventilatory support, may be highly suscep-
tible to development of Vent-IP/VILI and therefore may benefit from
genetic testing using Vent-IP/VILI markers. While SP/fibrosis gene ex-
pression markers can be more applicable for monitoring the develop-
ment and resolution of Vent-IP/VILI in patients who are already on
ventilatory support, SP/fibrosis gene polymorphisms/mutations can be
used for more individualized risk-benefit assessment and preventive
action prior to ventilation procedures.
CONCLUSIONS
As a pilot on new evidentiary approaches suitable for health care pol-
icy consideration, this study was focused on ventilatory safety as a
subject applicable to real-world health care decisions and comprehen-
sible to the wider medical community, including clinicians, re-
searchers, and regulators. However, this proof-of-concept study
demonstrates a wider applicability of this in silico approach, which is
based on the reutilization of pre-existing data and which thereby paves
the way for cost- and time-effective pharmacoepidemiologic and phar-
macogenetic solutions that are needed for implementing Precision
Medicine initiatives and enhancing medical product safety.
STUDY LIMITATIONS
The current study was limited to Vent-IP as a single ventilation-related event
identifiable by a combination of ICD-9 codes. The newly implemented ICD-9
codes for ventilation-associated pneumonia and “ventilation” pneumonitis
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(997.31 and 495.7, respectively) did not allow for gathering sufficient data;
VILI/VALI was precluded from the study due to a complete lack of ICD-9 codes.
The NIS analysis was unweighted.
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